Top ▲
Target not currently curated in GtoImmuPdb
Target id: 1798
Nomenclature: erb-b2 receptor tyrosine kinase 3
Abbreviated Name: HER3
Family: Type I RTKs: ErbB (epidermal growth factor) receptor family
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | 1 | 1342 | 12q13.2 | ERBB3 | erb-b2 receptor tyrosine kinase 3 | |
Mouse | 1 | 1339 | 10 77.1 cM | Erbb3 | erb-b2 receptor tyrosine kinase 3 | |
Rat | 1 | 1339 | 7q11 | Erbb3 | erb-b2 receptor tyrosine kinase 3 |
Previous and Unofficial Names ![]() |
lethal congenital contracture syndrome 2 | Glial growth factor receptor | LCCS2 | v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3 |
Database Links ![]() |
|
Alphafold | P21860 (Hs), Q61526 (Mm), Q62799 (Rn) |
BRENDA | 2.7.10.1 |
CATH/Gene3D | 3.80.20.20 |
ChEMBL Target | CHEMBL5838 (Hs) |
Ensembl Gene | ENSG00000065361 (Hs), ENSMUSG00000018166 (Mm), ENSRNOG00000004964 (Rn) |
Entrez Gene | 2065 (Hs), 13867 (Mm), 29496 (Rn) |
Human Protein Atlas | ENSG00000065361 (Hs) |
KEGG Enzyme | 2.7.10.1 |
KEGG Gene | hsa:2065 (Hs), mmu:13867 (Mm), rno:29496 (Rn) |
OMIM | 190151 (Hs) |
Orphanet | ORPHA160236 (Hs) |
Pharos | P21860 (Hs) |
RefSeq Nucleotide | NM_001005915 (Hs), NM_010153 (Mm), NM_017218 (Rn) |
RefSeq Protein | NP_001005915 (Hs), NP_034283 (Mm), NP_058914 (Rn) |
UniProtKB | P21860 (Hs), Q61526 (Mm), Q62799 (Rn) |
Wikipedia | ERBB3 (Hs) |
Selected 3D Structures ![]() |
|||||||||||||
![]() |
|
||||||||||||
![]() |
|
Enzyme Reaction ![]() |
||||
|
Natural/Endogenous Ligands ![]() |
neuregulin-1 {Sp: Human} |
neuregulin-2 {Sp: Human} |
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibitor Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TX2-121-1 (PubChem CID 78243759), a compound structurally related to TX1-85-1, is similarly reported to down-regulate HER3-dependent signalling [6]. |
Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Other Binding Ligands | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
DiscoveRx KINOMEscan® screen ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 3,10 |
![]() ![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: ERBB3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
Clinically-Relevant Mutations and Pathophysiology ![]() |
||||||||||
|
1. Barlaam B, Anderton J, Ballard P, Bradbury RH, Hennequin LF, Hickinson DM, Kettle JG, Kirk G, Klinowska T, Lambert-van der Brempt C et al.. (2013) Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. ACS Med Chem Lett, 4 (8): 742-6. [PMID:24900741]
2. Cho HS, Leahy DJ. (2002) Structure of the extracellular region of HER3 reveals an interdomain tether. Science, 297 (5585): 1330-3. [PMID:12154198]
3. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
4. Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R et al.. (2014) MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther, 13 (2): 410-25. [PMID:24282274]
5. Garner AP, Sprague EAR, Ettenberg SA, Kunz C, Haubst N, Elis W. (2014) Antibodies for epidermal growth factor receptor 3 (HER3). Patent number: US8735551 B2. Assignee: Novartis Ag.. Priority date: 20/08/2010. Publication date: 27/05/2014.
6. Lim SM, Xie T, Westover KD, Ficarro SB, Tae HS, Gurbani D, Sim T, Marto JA, Jänne PA, Crews CM et al.. (2015) Development of small molecules targeting the pseudokinase Her3. Bioorg Med Chem Lett, 25 (16): 3382-9. [PMID:26094118]
7. McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S et al.. (2012) Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther, 11 (3): 582-93. [PMID:22248472]
8. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, Linggi B, Kalra A, Paragas V, Bukhalid R et al.. (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal, 2 (77): ra31. [PMID:19567914]
9. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA. (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA, 107 (17): 7692-7. [PMID:20351256]
10. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
Type I RTKs: ErbB (epidermal growth factor) receptor family: erb-b2 receptor tyrosine kinase 3. Last modified on 11/07/2016. Accessed on 22/03/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1798.